Processa Pharmaceuticals, Inc. (OTCMKTS:PCSA) major shareholder James E. Besser acquired 30,000 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were acquired at an average price of $4.04 per share, for a total transaction of $121,200.00. Following the purchase, the insider now owns 405,000 shares of the company’s stock, valued at $1,636,200. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
PCSA opened at $4.43 on Friday. Processa Pharmaceuticals, Inc. has a fifty-two week low of $3.40 and a fifty-two week high of $18.00. The company’s 50-day moving average price is $7.35 and its 200 day moving average price is $7.86. The company has a current ratio of 0.30, a quick ratio of 0.30 and a debt-to-equity ratio of 0.01.
Processa Pharmaceuticals (OTCMKTS:PCSA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.13) earnings per share for the quarter.
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition.
Recommended Story: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Processa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Processa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.